Albert Bourla is on top of the world—and in some ways, his job has never been tougher. The Pfizer CEO took over at the 173-year-old pharma giant just a year before the pandemic; he was in the beginning phases of a corporate transformation—aimed at making Pfizer a breakthrough factory (he had no interest in “incremental science”)—when the novel coronavirus SARS-CoV-2 surfaced, and Pfizer, along with its Germany-based partner